Can a two-drug combo beat the HTLV-1 virus?
NCT ID NCT07555431
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial compares the drug dolutegravir alone versus dolutegravir combined with tenofovir in 146 adults with HTLV-1 infection and related symptoms. The main goal is to see if the combination lowers the virus level more effectively and improves pain, spasticity, and muscle strength over 48 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dolutegravir and tenofovir disoproxil fumarate
- What this could lead to
- If successful, this could point toward a more effective treatment to lower the virus and ease symptoms like pain and muscle weakness in people with HTLV-1.
- What could go wrong
- This is a small, early-phase trial (Phase 2) with only 146 participants. The combination has not been tested before, so it may not work better than dolutegravir alone, and side effects are not yet well understood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HTLV I ASSOCIATED MYELOPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital Universitário Professor Edgard Santos
RECRUITINGSalvador, Estado de Bahia, 40110-060, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.